Vu Binh Duc, Nguyen Hung Quang, Le Chiem Quang, Nguyen Cuong Ba, Le Tuong Quang, Nguyen Anh Vu-Bao, Nguyen Thanh Hoang, Le Tai Phu, Nguyen Hieu Van
National Institute of Hematology and Blood Transfusion, Hanoi City, Vietnam.
Department Of Hematology And Blood Transfusion, Hanoi Medical University, Vietnam.
SAGE Open Med. 2025 Apr 27;13:20503121251334508. doi: 10.1177/20503121251334508. eCollection 2025.
The prognostic factors of patients diagnosed with marginal zone B-cell lymphoma at the National Institute of Hematology and Blood Transfusion between January 2014 and January 2024 were analyzed.
This cross-sectional descriptive study included 86 newly diagnosed and treated marginal zone B-cell lymphoma patients. Myelogram, histopathology, and immunohistochemical staining were performed for all patients. Diagnosis and classification were conducted according to the WHO 2008 criteria, while disease staging was determined using the Ann Arbor staging system.
All three subtypes of marginal zone B-cell lymphoma were identified: mucosa-associated lymphoid tissue lymphoma (73.3%), nodal marginal zone lymphoma (20.9%), and splenic marginal zone lymphoma (5.8%). The most frequently affected extranodal sites were the stomach (25.6%) and eyes (24.4%). The likelihood of stages III-IV disease was found to be 14 times higher in patients with B symptoms, 17 times higher in those with elevated lactate dehydrogenase, 34 times higher in those with increased B2-M levels, and 5.7 times higher in those with a Ki67 index > 30%. Bone marrow invasion was observed to be 14.8 times more likely in patients with elevated lactate dehydrogenase, 40 times more likely in those with increased B2-M levels, and 4.4 times more likely in those with a Ki67 index > 30%. A significant correlation was identified among hemoglobin concentration, lactate dehydrogenase, B2-M, and Ki67, indicating their potential as prognostic markers.
Lactate dehydrogenase, B2-M, and Ki67 were found to be significantly associated with the prognosis of patients with marginal zone B-cell lymphoma.
分析2014年1月至2024年1月期间在国立血液学和输血研究所被诊断为边缘区B细胞淋巴瘤患者的预后因素。
这项横断面描述性研究纳入了86例新诊断并接受治疗的边缘区B细胞淋巴瘤患者。对所有患者进行了骨髓检查、组织病理学检查和免疫组化染色。诊断和分类依据世界卫生组织2008年标准进行，而疾病分期则使用Ann Arbor分期系统确定。
边缘区B细胞淋巴瘤的所有三种亚型均被识别出来：黏膜相关淋巴组织淋巴瘤（73.3%）、结内边缘区淋巴瘤（20.9%）和脾边缘区淋巴瘤（5.8%）。最常受累的结外部位是胃（25.6%）和眼睛（24.4%）。发现有B症状的患者出现III-IV期疾病的可能性高14倍，乳酸脱氢酶升高的患者高17倍，B2-M水平升高的患者高34倍，Ki67指数>30%的患者高5.7倍。观察到乳酸脱氢酶升高的患者骨髓侵犯的可能性高14.8倍，B2-M水平升高的患者高40倍，Ki67指数>30%的患者高4.4倍。血红蛋白浓度、乳酸脱氢酶、B2-M和Ki67之间存在显著相关性，表明它们作为预后标志物的潜力。
发现乳酸脱氢酶、B2-M和Ki67与边缘区B细胞淋巴瘤患者的预后显著相关。
